Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. - Wikidata - wikimedia - TriplyDB

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

http://www.wikidata.org/entity/Q33997854

about

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia Structural reengineering of imatinib to decrease cardiac risk in cancer therapy European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Role for the Unfolded Protein Response in Heart Disease and Cardiac Arrhythmias Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy Pharmacology and rationale for imatinib in the treatment of scleroderma Cardiac effects of anticancer therapy in the elderly Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.Principal component analysis-based unsupervised feature extraction applied to in silico drug discovery for posttraumatic stress disorder-mediated heart disease Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Adaptability in protein structures: structural dynamics and implications in ligand design.Intersection of cardiology and oncology clinical practices.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.A cell-based biosensor for real-time detection of cardiotoxicity using lensfree imaging.High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

P2860

Q21142738-1247D400-965A-4FAD-9E3F-21C299808DF5 Q24605527-31E5B063-A303-43BA-914B-1AEFDF80B1EB Q24685557-24FB745D-79F0-4CA3-9E4C-75228847313E Q26749324-0D8160A0-8663-4AC6-9EDF-0FAA9993D555 Q26771256-C4964972-A5D0-4372-B0FA-09978A72767E Q26797138-81B1F5A7-E0BB-410F-94E3-03D31D01BE04 Q26825153-F514DF22-FFC5-4E03-BD16-63C1528E5A1D Q26863244-BDA97075-564A-4508-B21A-99B78F46639C Q26865766-4FA35054-D434-4FDD-91F5-2AD2441B5F20 Q27013665-38F00BED-8CF5-48A7-9282-576AFCB97A83 Q27023074-F652487F-F47A-49CF-AD93-9F0337C0E662 Q27027354-D48C3E71-0DF0-4871-BD5A-92689A4005CA Q28087776-769CE45B-644D-4045-81E3-DB8F7A0A4F34 Q28276103-00EFF9E5-D474-4968-BF6C-7259370AC8E3 Q28281770-986A4694-B09E-4FD4-AA05-EFFC6767B1A3 Q28296128-37E5ABAD-E0C9-43E8-9202-F62583C62304 Q28395122-ADA5732F-417B-43CB-BD7C-B26CAE07298F Q28476104-5F1D7877-6751-437D-9764-9576D15D567D Q28586705-446DCA95-DB39-4714-90F3-A37119EBCFA8 Q28590516-6C2B59F9-F1AF-4A07-9F42-E9041771BFE2 Q30008882-EE34FBB6-327E-42FE-A634-1CEB7FDFDF90 Q30242015-4D384F9B-78D9-41E4-8310-01F8CEEA18DC Q30357974-81A08771-E570-4918-887D-623A25065A7B Q30428702-6A81CD5D-7F53-4EC6-BE4D-9806A252E0CA Q30446453-4B9CC239-96AA-4A8C-B6CD-20C09C32A1D1 Q30485073-35A1EC8B-0601-48E1-8207-9E75898EBF8E Q30492863-5AE0393E-475D-4606-993F-29F451CC0320 Q30538150-36B91666-0B7D-40E5-8720-816E861245A0 Q30847302-4FB2E755-836A-42B2-9D01-97F054ED70AD Q30884142-7125BF74-BDEF-4422-B411-243E87476738 Q31037843-2FB739B8-EA39-4FAF-A907-A1F84C3BFBC4 Q33308713-AF6B34B0-4E60-4138-9E0D-18A69DEC60EA Q33383954-7262E9B6-8D91-4ED2-BC48-DB12DB9C6A62 Q33392977-36B2ABB5-1629-4718-880E-B2654A0080B4 Q33401360-E6DABA6C-E4E6-4BBA-96D0-EEEE8EDAC976 Q33408049-B7A2BE4B-4DFA-4452-90FA-972ABBDD88E6 Q33419794-A81B71DF-C6AC-4BCA-A341-54E52AC8B1CC Q33482818-565CDD60-0786-48D9-BBEC-6ABE7A4D9281 Q33569566-18F5750A-E977-479B-8C16-69FB15FC3936 Q33573760-607EF0EE-F848-4ECF-A468-B64113EFE631

P2860

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

http://www.wikidata.org/entity/Q33997854

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

@ast

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

@en

type

label

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

@ast

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

@en

prefLabel

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

@ast

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

@en

P1433

Q33997854-98CD7B71-9C4B-4134-B23B-A0E0A9AA8ABA

P1476

Q33997854-57EADA7F-F952-4490-9F11-2BDB0130733A

P2093

Q33997854-097C0671-A12D-4BAC-A5A2-ADE0AEBE26B3

Q33997854-14BDD674-3367-4EE4-B192-25484077E405

Q33997854-23C49B6F-FD49-4DF2-84F5-A7975AEEC585

Q33997854-3C3E1F15-11D0-4566-9C82-62C6A26A7428

Q33997854-66DF671D-3EB4-41A1-A026-2C09C332C083

Q33997854-6D580848-0263-4E7C-B81F-AE6EA65819FE

Q33997854-7A1ACD15-9738-4330-B0CC-9F147C3397DE

Q33997854-84062EBE-A5D3-4F57-93BC-219FEEC7F231

Q33997854-85DC6119-FB78-441F-8E25-32CB888C10F3

Q33997854-8F025AE1-4A51-447C-B267-74A537069BB8

P2888

Q33997854-45235C76-45D6-449C-8521-FE5805F07D46

P304

Q33997854-70E369D3-E532-4C61-9BA2-09B3FFCB4BA8

P31

Q33997854-0E610D20-0D79-4227-9A65-0320B2CC7381

P356

Q33997854-701BE403-FFD7-413A-995D-FDD32BDDA121

P407

Q33997854-FEE33D4E-1AA4-49C0-BCDA-9F7C04997331

P433

Q33997854-F8DE12C2-43C3-4F10-B518-BF4649E9CD1F

P478

Q33997854-8DE7ED99-FCF1-4122-91B6-A9E054E0ADF3

P50

Q33997854-75027FF6-DC53-44B6-82F8-5576A8435D76

P577

Q33997854-1B628BC8-2E26-4CFF-9D0F-E5154AA40FC8

P5875

Q33997854-62996E06-EB29-40C4-A4D5-ABB28EEA9BA9

P698

Q33997854-105A3CD8-AD12-45D5-B8C8-5DF17046BBB8

P356

P1433

Nature Medicine

P1476

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

@en

P2093

Anthony Rosenzweig

http://www.w3.org/2001/XMLSchema#string

Brian Walters

http://www.w3.org/2001/XMLSchema#string

Cara Beahm

http://www.w3.org/2001/XMLSchema#string

Cezar Iliescu

http://www.w3.org/2001/XMLSchema#string

Fred J Clubb

http://www.w3.org/2001/XMLSchema#string

Jean-Bernard Durand

http://www.w3.org/2001/XMLSchema#string

Joseph Alroy

http://www.w3.org/2001/XMLSchema#string

Luanda Grazette

http://www.w3.org/2001/XMLSchema#string

Richard A Van Etten

http://www.w3.org/2001/XMLSchema#string

Richard Patten

http://www.w3.org/2001/XMLSchema#string

P2888

P304

908-916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1446

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6924257

http://www.w3.org/2001/XMLSchema#string

P698

16862153

http://www.w3.org/2001/XMLSchema#string